Introduction
There is marked heterogeneity among persons with schizophrenia regarding their disease course and response to pharmacological treatment, as well as notable differences among available interventions. 1 Determining the optimal medication for an individual patient requires consideration of prior history of response (or lack thereof) for the array of problematic symptoms that may be present, prior history of tolerability (both subjective and objective), potential drug-drug interactions, and potential interactions between the proposed intervention and existing comorbid conditions. 2 When combining a patient risk profile with an antipsychotic adverse event profile, physicians may quickly run out of tolerable treatment options for individual patients, despite the availability of many antipsychotics, suggesting a need for additional treatment options with better tolerability and without compromising efficacy. 3 The years 2015 and 2016 have ushered in several newer options for the management of schizophrenia for both acute and maintenance treatment (Table 1) . These include the oral dopamine partial agonist antipsychotics brexpiprazole and cariprazine, another formulation of long-acting injectable aripiprazole that can be administered every 6 weeks at its highest dose strength, and a new formulation of paliperidone palmitate that can be administered every 3 months in persons already stabilized on monthly paliperidone palmitate. Among new compounds in late stages of development is another formulation of long-acting injectable aripiprazole that can be administered every 8 weeks, a once-monthly long-acting formulation of risperidone that can be injected subcutaneously, a new and novel antipsychotic known as ITI-007 and recently given the name of lumateperone, and 2 options for the treatment of tardive dyskinesia that build upon the mechanism of action of tetrabenazine: deutetrabenazine and valbenazine (Table 1) . This overview will survey the key points regarding each of these interventions. Not discussed are those molecules that have essentially failed their Phase III development programs-pomaglumetad methionil, bitopertin, and encenicline-agents that initially showed promise in the treatment of cognitive and/or negative symptoms seen in persons with schizophrenia but where the Phase III studies were largely unsuccessful. 4, 5 What's New?
Brexpiprazole
Brexpiprazole was approved by the U.S. Food and Drug Administration (FDA) in 2015 and launched the same year for the treatment of schizophrenia and for adjunctive therapy to antidepressants for the treatment of major depressive disorder. [6] [7] [8] Brexpiprazole is a "serotonindopamine activity modulator" in that it is a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, with similar potency, and an antagonist at serotonin 5-HT2A and adrenergic alpha 1B/2C receptors. 9 The recommended dose range of brexpiprazole for the treatment of schizophrenia is 2-4 mg/day once daily, with or without food. Titration is required, and the product label recommends starting with 1 mg/day and increasing to 2 mg/day on Day 5 to Day 7, then to 4 mg/day on Day 8. Brexpiprazole is metabolized by both CYP2D6 and CYP3A4. Approval for the treatment of schizophrenia was based on 2 positive, 6-week, Phase III randomized controlled trials in acute schizophrenia that demonstrated superiority of brexpiprazole over placebo on change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score. 10, 11 Of clinical relevance is the rate of response, as defined in these trials as achieving a change from baseline ≥30% in PANSS total score or Clinical Global Impressions-Improvement (CGI-I) score of 1 (very much improved) or 2 (much improved). Pooled responder rates were 46% for brexpiprazole 2-4 mg/day vs 31% for placebo, resulting in a number needed to treat (NNT) of 7. In a 52-week, randomized withdrawal study, 12 significantly fewer patients relapsed in the brexpiprazole group compared with placebo (13.5% vs 38.5%), resulting in a NNT of 4. Although the most commonly encountered adverse event (incidence ≥4% and at least twice the rate of placebo) is increased weight, short-term weight gain appears modest. 6 Approximately 10% of patients receiving brexpiprazole 1-4 mg/day gained ≥7% body weight from baseline vs 4% for those randomized to placebo, resulting in a number needed to harm (NNH) of 17 in the 6-week trials. However more outliers with an increase of ≥7% of body weight were evident in open-label, 52-week safety studies, 13 with the product label noting that 20% of patients demonstrated a ≥7% increase in body weight and 10% demonstrated a ≥7% decrease in body weight. 6 Effects on glucose and lipids were generally small. Rates of akathisia as an adverse event were 5.5% for the pooled doses of brexpiprazole 1-4 mg/day vs 4.6% for placebo, yielding a NNH of 112. Minimal effects on prolactin were observed, and no clinically relevant effects on the electrocardiogram (ECG) QTc interval were evident.
Cariprazine
Cariprazine was approved by the FDA in 2015 and launched in 2016 for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder. 14, 15 Cariprazine is a "dopamine D3-preferring D3/D2 receptor partial agonist" in that its binding affinity is an order of magnitude higher for dopamine D3 receptors than it is for dopamine D2 receptors. Cariprazine is also a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors. The recommended dose range of cariprazine for the treatment of schizophrenia is 1.5-6 mg/d; titration is thus not required, as the starting dose of 1.5 mg/d is potentially therapeutic. Cariprazine is administered once daily, with or without food. Cariprazine's pharmacokinetic profile through the CYP3A4 enzyme system is of interest because 1 of the 2 active metabolites, didesmethyl-cariprazine, has a half-life that is substantially longer than that for cariprazine; the half-life based on time to reach steady state is approximately 2-4 days for cariprazine and approximately 1-3 weeks for didesmethyl-cariprazine. Systemic exposure to didesmethyl-cariprazine is several times higher than that for cariprazine and thus didesmethyl-cariprazine is the predominant active moiety. This long half-life allows for the possibility of increasing the dosing interval; for example, the product label recommends that for patients . http://dx.doi.org/10.1017/S1092852916000729 taking 1.5 mg daily, the dosing regimen should be adjusted to every other day when cariprazine is co-administered with a strong CYP3A4 inhibitor. There were three positive, 6-week, Phase II/III, randomized controlled trials in acute schizophrenia that demonstrated superiority of cariprazine over placebo on change from baseline on the PANSS total score. [16] [17] [18] In these studies response was defined as achieving a change from baseline ≥30% in PANSS total score, a more narrow definition that that used in the brexpiprazole trial reports. Pooled responder rates were 31% for cariprazine 1.5-6 mg/d vs 21% for placebo, resulting in a NNT of 10. In a long-term, randomized withdrawal study, 19 significantly fewer patients relapsed in the cariprazine group compared with placebo (24.8% vs 47.5%), resulting in a NNT of 5. The most commonly encountered adverse events (incidence ≥5% and at least twice the rate of placebo) 14 
Aripiprazole lauroxil
Aripiprazole lauroxil is N-lauroyloxymethyl aripiprazole, an N-acyloxymethyl prodrug of aripiprazole, and is supplied in prefilled syringes as an aqueous suspension, It was approved for the treatment of schizophrenia in 2015. 20, 21 
3-Month paliperidone palmitate
A 3-month formulation of paliperidone palmitate became available in 2015 and is approved by the FDA for use in people with schizophrenia who have been treated with the once-monthly formulation of paliperidone palmitate for at least 4 months. 23 Denser, and with a different particle size than the once-monthly formulation, the doses available in the prefilled syringes in aqueous solution are sufficiently small in volume that they can be administered in the deltoid muscle, although gluteal injection remains an option. Dose is determined by multiplying the once-monthly dose by 3.5. Approval in the US was based on a randomized withdrawal study, 24 where fewer patients randomized to 3-month paliperidone palmitate relapsed compared with placebo (at study end 9% vs 29%), resulting in a NNT of 5. Also available is a non-inferiority study comparing 3-month paliperidone palmitate with 1-month paliperidone palmitate, with no placebo control. 25 A similar percentage of patients in both groups experienced a relapse event during the double-blind phase of this long term study (8% vs 9%, for the 3-month and 1-month formulations, respectively). Adverse event rates were similar between the 2 formulations in that study.
What's Different?
Oral dopamine receptor partial agonists Similar to aripiprazole, brexpiprazole and cariprazine are dopamine receptor partial agonists. 26 There are several key differences however. First, their pharmacodynamic profiles differ. Compared with aripiprazole, brexpiprazole has lower intrinsic activity at the dopamine D2 receptor and has an approximately 10-fold higher affinity for serotonin 5-HT1A and 5-HT2A receptors, potentially enhancing tolerability. 9 When cariprazine was compared with aripiprazole in functional assays for dopamine D2 and D3 receptors, similar D2 and higher D3 antagonistpartial agonist affinity and a 3-to 10-fold greater D3 vs D2 selectivity was observed for cariprazine. 27 Whether targeting the dopamine D3 receptor over the dopamine D2 receptor is clinically advantageous remains unknown, but theoretically, dopamine D3 preferring agents may exert procognitive effects. 28 Pharmacokinetic profiles differ as well. Although all 3 medications have lengthy half-lives (range 2-4 days) compared with many other antipsychotics (usually 24 hours or less), the half-life of the predominant active metabolite of cariprazine is 1-3 weeks. The approved indications also differ. Although all 3 are approved for the treatment of schizophrenia, both aripiprazole and brexpiprazole are also approved for adjunctive treatment of major depressive disorder, and both aripiprazole and cariprazine are also approved for acute treatment of manic or mixed episodes associated with bipolar I disorder. In addition, aripiprazole is improved for a number of different disease states in the pediatric population. Regarding efficacy in the treatment of schizophrenia, both acute and maintenance treatment outcomes appear similar, 26, 29 but the adverse event profiles differ. 26 By indirect comparison, for the indication of schizophrenia, the rank order for propensity for weight gain ≥7% from baseline appears to be brexpiprazole (NNH vs placebo 17) > aripiprazole (NNH 21) > cariprazine (NNH 34); the propensity for somnolence, aripiprazole (NNH 20) > brexpiprazole (NNH 50) > cariprazine (NNH 100); and the propensity for akathisia, cariprazine (NNH 15) > aripiprazole (NNH 25) > brexpiprazole (NNH 112).
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Aripiprazole long-acting injectables
Aripiprazole lauroxil and aripiprazole monohydrate are 2 long-acting injectable antipsychotic formulations that result in the slow, predictable release of aripiprazole molecules from the injection site. 21 Both are approved for the treatment of schizophrenia, and, depending on the dose of aripiprazole lauroxil, both can be administered in either the deltoid or gluteal muscle. Some differences include the method of preparation. Aripiprazole lauroxil is packaged in a prefilled syringe in aqueous solution, whereas aripiprazole monohydrate is a powder that is mixed with water to form an aqueous suspension. Preparation of aripiprazole monohydrate is, however, simplified when the prefilled, dual-chambered syringes are used rather than the vial kits. Other "amenities" of care differ as well. There are multiple dose strengths and flexibility in dosing intervals for aripiprazole lauroxil (6 weeks vs 4 weeks), which may be considered advantageous for some patients, whereas for aripiprazole monohydrate, the smaller needle gauge (23G vs 21G for the smallest option) and the requirement for fewer days of overlapping oral antipsychotic after the first injection (14 vs 21 days) may be important for other patients. There are also differences in the length of time between injections that may otherwise require restarting oral supplementation. For the higher doses of aripiprazole lauroxil, injections can be up to 1 month late and not trigger the need for oral medication to supplement the injection. If necessary, aripiprazole lauroxil can also be administered as early as 2 weeks following the prior injection. Because of the availability of multiple dose strengths of aripiprazole lauroxil, co-administration with a CYP3A4 inducer for greater than 14 days remains a possibility, in contrast to aripiprazole monohydrate where this cannot be done. 30 For both aripiprazole lauroxil and aripiprazole monohydrate, their overall tolerability profiles are consistent with what is known about oral aripiprazole, and in the acute, placebocontrolled clinical trials, incidence of injection site pain appeared similar and within the range of 3.9-5.8%. 21 In terms of clinical trial evidence, there is far more in the scientific literature for aripiprazole monohydrate than for aripiprazole lauroxil. Although both interventions have a published acute efficacy study, aripiprazole monohydrate demonstrated superiority to placebo in delaying the time to relapse in a double-blind, randomized, maintenance study, 31 and demonstrated noninferiority to oral aripiprazole in relapse rates in 2 double-blind, randomized, maintenance studies. 32, 33 In addition, a head-to-head comparison with paliperidone palmitate showed superiority for aripiprazole monohydrate on a quality-of-life scale, 34 and pharmacoeconomic models further establish aripiprazole monohydrate as a dominant choice vs paliperidone palmitate when higher doses of the latter are utilized. 35 
Paliperidone palmitate formulations
The 3-month formulation of paliperidone palmitate is similar to that for the 1-month formulation but with a larger particle size, which provides an extended, sustained release of paliperidone and permits the significantly extended dosing interval. 36 As a consequence, the solution is denser and requires vigorous shaking for at least 15 seconds prior to administration of the prefilled syringe, 23 compared to the 10 seconds required for the 1-month formulation. 37 Other key differences are the instructions regarding what to do in case of delays between injections and missed maintenance doses. With the 3-month formulation, patients may be given the EMERGING THERAPIES IN SCHIZOPHRENIA 7 injection up to 2 weeks before or after the 3-month time point. 23 If more than 3.5 months (up to but less than 4 months) have elapsed since the last injection, the previously administered dose should be administered as soon as possible, then continue with the 3-month injections following this dose. 23 If 4 months up to and including 9 months have elapsed since the last injection, a re-initiation regimen involving the 1-month preparation will need to be used. 23 The product label also cautions that the 3-month formulation must be administered using only the thin wall needles that are provided in order to reduce the risk of blockage, 23 and that these needles are not interchangeable with those supplied with the 1-month formulation or with other regular, commercially available needles.
What's Next?
Lumateperone Lumateperone (ITI-007) is in Phase III of clinical development for the treatment of schizophrenia. [38] [39] [40] [41] [42] [43] In contrast to currently available first-line, second-generation antipsychotics, lumateperone is a potent antagonist at the 5-HT2A receptor (Ki 0.54 nM) with 60-fold less affinity for D2 receptors (Ki 32 nM), allowing full saturation of 5-HT2A receptors, even at modest levels of dopamine receptor occupancies. 38, 41 Moreover, at D2 receptors, lumateperone is a presynaptic partial agonist and postsynaptic antagonist with functional mesolimbic and mesocortical selectivity. Lumateperone has also been described as a "dopamine phosphoprotein modulator." 39, 43 In addition, lumateperone increases phosphorylation of subunits of N-methyl-D-aspartate (NMDA) receptors. Lumateperone has activity at the serotonin transporter (Ki 62 nM) as well. Relatively low binding affinities are observed at histaminergic H1, serotonin 5-HT2C, and muscarinic receptors, predicting an overall favorable tolerability profile. Lumateperone is administered once daily in the morning with no titration. 40 In a 4-week, Phase II clinical trial of lumateperone in 335 patients with acute schizophrenia, statistically significant improvement vs placebo for the primary endpoint (change from baseline in the PANSS total score) at the dose of 60 mg/d (but not 120 mg/d) was observed. Lumateperone was well tolerated, as evidenced by low discontinuation and adverse event rates, and was associated with a benign metabolic profile, as evidenced by significantly lower levels of prolactin, fasting glucose, total cholesterol, and triglycerides than risperidone 4 mg/d, which served as an active control. In a 4-week, Phase III trial in 450 patients with acute schizophrenia, 60 mg/d (but not 40 mg/d) demonstrated efficacy, with statistically significant superiority over placebo at Day 28, as measured by the PANSS total score. 39 Consistent across both studies, lumateperone was well-tolerated, as evidenced by a motoric, metabolic, and cardiovascular profile similar to placebo, and no clinically significant changes in akathisia, extrapyramidal symptoms, prolactin, body weight, glucose, insulin, lipids, or the ECG QTc interval. 40 The most frequently encountered adverse event (incidence ≥ 5% and at least twice the rate of placebo) was sedation/somnolence. In the reported Phase III trial, rates were 17.3% for 60 mg vs 4.0% for placebo for somnolence (mild to moderate), 12.0% for 60 mg vs 5.4% for placebo for sedation (mild), and 5.3% for 60 mg vs 1.3% for placebo for fatigue (mild to moderate), 40 resulting in NNH values vs placebo of 8,
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, and 25, respectively. Enrollment in a second Phase III trial in patients with schizophrenia has been completed (NCT02469155). In addition to schizophrenia, lumateperone is being studied in Phase III trials for bipolar depression and for behavioral disturbances in patients with dementia. 39, 43 A long-acting injectable formulation is also being developed. 43 
Deutetrabenazine and valbenazine
Deutetrabenazine (SD-809) and valbenazine (NBI-98854) are medications in Phase III of clinical development for the treatment of tardive dyskinesia (TD). TD has not gone away with the emergence of second-generation antipsychotics, 44 and remains a significant treatment issue for persons on chronic antipsychotic therapy. 45 TD is characterized by involuntary, repetitive, purposeless movements of the tongue, jaw, lips, face, trunk, upper extremities, lower extremities, and respiratory system, and can be quite stigmatizing. 46 Moreover, available treatments have been generally ineffective or limited. 47 Tetrabenazine is an "orphan drug" for the treatment of choreiform movements associated with Huntington's disease that is also used to treat TD "off-label." 48 The mechanism of action of tetrabenazine is by inhibiting the vesicular monoamine transporter 2 (VMAT-2), resulting in depletion of synaptic dopamine. Unfortunately its pharmacokinetic profile requires frequent dosing, and 2 derivatives of the β-tetrabenazine enantiomer are antagonists at the dopamine D2 receptor and can induce sedation and parkinsonism, with adverse effects being more pronounced in the presence of CYP2D6 inhibitors. 49 Deutetrabenazine and valbenazine are alternatives to tetrabenazine. Both are also VMAT-2 inhibitors. Deutetrabenazine differs from tetrabenazine in that deuterium atoms (a nontoxic and nonradioactive form of hydrogen) take the place of hydrogen atoms on the molecule at the sites of primary metabolism. [50] [51] [52] Because deuterium has a greater mass relative to hydrogen, deuterium forms a stronger bond with carbon, and thus more energy is required for cleavage, thus slowing metabolism, allowing less frequent dosing, and improving tolerability. 50 Valbenazine is a new molecular entity that is metabolized to an active derivative (+ )-α-dihydrotetrabenazine; the undesirable dihydrotetrabenazine derivatives of β-tetrabenazine are not produced. 49 In a randomized, 6-week, double-blind, placebo-controlled, dose-titration Phase II study, once-daily valbenazine significantly improved tardive dyskinesia and was well tolerated. 54 Responder rates (defined as a ≥50% improvement in the AIMS score) were 48.9% for valbenazine vs 18.2% for placebo, resulting in a NNT of 4. CGI-I scores of "very much improved" or "much improved" were observed in 66.7% vs 15.9% of participants randomized to valbenazine and placebo, respectively, for a NNT of 2. Also available are the results of a 6-week Phase III study where valbenazine was superior to placebo on change from baseline on the AIMS total score with a large effect size (Cohen's d = 0.90); however, categorical efficacy outcomes were not reported and NNT could not be calculated. 55 An openlabel study to evaluate the safety and tolerability of valbenazine administered once daily for a total of 48 weeks of treatment is in progress (NCT02405091).
New long-acting injectable agents
In development is a new formulation of aripiprazole lauroxil that consists of 1064 mg administered intramuscularly every 2 months. 56 Subcutaneous injection is another potential route for administration of long-acting formulations of antipsychotics, and is being developed for risperidone (RBP-7000). [57] [58] [59] [60] [61] RBP-7000 uses a delivery system that is a sterile, polymeric solution of a biodegradable poly(DL-lactideco-glycolide), or poly-L-lactic acid copolymer, dissolved in N-methyl-2-pyrrolidone, a water-miscible, biocompatible solvent. 60 When starting RBP-7000, oral supplementation with antipsychotics is not required. In an 8-week study in patients with acute schizophrenia, doses of subcutaneous risperidone 90 mg and 120 mg every 4 weeks were superior to placebo on changes in the PANSS total score. 60 Rates of adverse events related to the injection were similar for RBP-7000 as for placebo.
Conclusions
Incremental advances are being made in the development of second-generation antipsychotics for the treatment of schizophrenia. The major differentiators among the new and upcoming oral choices center on tolerability. Differences among new and upcoming long-acting injectable antipsychotics revolve around increasing the time interval between each injection. On the horizon are new agents for the specific indication of tardive dyskinesia, a condition that has not been eliminated by the advent of second-generation antipsychotics.
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